260 related articles for article (PubMed ID: 9617321)
21. The combination of green tea and tamoxifen is effective against breast cancer.
Sartippour MR; Pietras R; Marquez-Garban DC; Chen HW; Heber D; Henning SM; Sartippour G; Zhang L; Lu M; Weinberg O; Rao JY; Brooks MN
Carcinogenesis; 2006 Dec; 27(12):2424-33. PubMed ID: 16785249
[TBL] [Abstract][Full Text] [Related]
22. A new triphenylethylene derivative, TAT-59; hormone receptors; insulin-like growth factor 1; and growth suppression of hormone-dependent MCF-7 tumors in athymic mice.
Iino Y; Takai Y; Ando T; Ohwada S; Yokoe T; Sugamata N; Takei H; Horiguchi J; Iijima K; Morishita Y
Cancer Chemother Pharmacol; 1994; 34(5):372-6. PubMed ID: 8070003
[TBL] [Abstract][Full Text] [Related]
23. Hormone dependency and the action of tamoxifen in human mammary carcinoma cells.
Roos W; Huber P; Oeze L; Eppenberger U
Anticancer Res; 1982; 2(3):157-62. PubMed ID: 7125602
[TBL] [Abstract][Full Text] [Related]
24. A dietary supplement for female sexual dysfunction, Avlimil, stimulates the growth of estrogen-dependent breast tumors (MCF-7) implanted in ovariectomized athymic nude mice.
Ju YH; Doerge DR; Helferich WG
Food Chem Toxicol; 2008 Jan; 46(1):310-20. PubMed ID: 17919800
[TBL] [Abstract][Full Text] [Related]
25. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
Núñez NP; Jelovac D; Macedo L; Berrigan D; Perkins SN; Hursting SD; Barrett JC; Brodie A
Clin Cancer Res; 2004 Aug; 10(16):5375-80. PubMed ID: 15328175
[TBL] [Abstract][Full Text] [Related]
26. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model.
Gottardis MM; Jordan VC
Cancer Res; 1987 Aug; 47(15):4020-4. PubMed ID: 3607747
[TBL] [Abstract][Full Text] [Related]
27. Tumor-inhibiting potential of ZK 112.993, a new progesterone antagonist, in hormone-sensitive, experimental rodent and human mammary tumors.
Schneider MR; Michna H; Nishino Y; Neef G; el Etreby MF
Anticancer Res; 1990; 10(3):683-7. PubMed ID: 2369083
[TBL] [Abstract][Full Text] [Related]
28. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment.
Lykkesfeldt AE; Larsen SS; Briand P
Int J Cancer; 1995 May; 61(4):529-34. PubMed ID: 7759159
[TBL] [Abstract][Full Text] [Related]
29. Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer.
Chander SK; McCague R; Luqmani Y; Newton C; Dowsett M; Jarman M; Coombes RC
Cancer Res; 1991 Nov; 51(21):5851-8. PubMed ID: 1933854
[TBL] [Abstract][Full Text] [Related]
30. A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor.
Foster PA; Chander SK; Newman SP; Woo LW; Sutcliffe OB; Bubert C; Zhou D; Chen S; Potter BV; Reed MJ; Purohit A
Clin Cancer Res; 2008 Oct; 14(20):6469-77. PubMed ID: 18927286
[TBL] [Abstract][Full Text] [Related]
31. Antiestrogenic effect of 20S-protopanaxadiol and its synergy with tamoxifen on breast cancer cells.
Yu Y; Zhou Q; Hang Y; Bu X; Jia W
Cancer; 2007 Jun; 109(11):2374-82. PubMed ID: 17464948
[TBL] [Abstract][Full Text] [Related]
32. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.
Lu M; Miller KD; Gokmen-Polar Y; Jeng MH; Kinch MS
Cancer Res; 2003 Jun; 63(12):3425-9. PubMed ID: 12810680
[TBL] [Abstract][Full Text] [Related]
33. 2-Phenylbenzo[b]furans: relationship between structure, estrogen receptor affinity and cytostatic activity against mammary tumor cells.
Erber S; Ringshandl R; von Angerer E
Anticancer Drug Des; 1991 Nov; 6(5):417-26. PubMed ID: 1764164
[TBL] [Abstract][Full Text] [Related]
34. Orally administered endoxifen is a new therapeutic agent for breast cancer.
Ahmad A; Ali SM; Ahmad MU; Sheikh S; Ahmad I
Breast Cancer Res Treat; 2010 Jul; 122(2):579-84. PubMed ID: 20052538
[TBL] [Abstract][Full Text] [Related]
35. Design and synthesis of potent antitumor 5,4'-diaminoflavone derivatives based on metabolic considerations.
Akama T; Ishida H; Shida Y; Kimura U; Gomi K; Saito H; Fuse E; Kobayashi S; Yoda N; Kasai M
J Med Chem; 1997 Jun; 40(12):1894-900. PubMed ID: 9191967
[TBL] [Abstract][Full Text] [Related]
36. Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha.
Chisamore MJ; Ahmed Y; Bentrem DJ; Jordan VC; Tonetti DA
Clin Cancer Res; 2001 Oct; 7(10):3156-65. PubMed ID: 11595710
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effect of triphenylethylene derivative (TAT-59) against human breast carcinoma xenografts in nude mice.
Koh J; Kubota T; Asanuma F; Yamada Y; Kawamura E; Hosoda Y; Hashimoto M; Yamamoto O; Sakai S; Maeda K
J Surg Oncol; 1992 Dec; 51(4):254-8. PubMed ID: 1434657
[TBL] [Abstract][Full Text] [Related]
38. Development and characterization of a tamoxifen-resistant breast carcinoma xenograft.
Naundorf H; Becker M; Lykkesfeldt AE; Elbe B; Neumann C; Büttner B; Fichtner I
Br J Cancer; 2000 Jun; 82(11):1844-50. PubMed ID: 10839300
[TBL] [Abstract][Full Text] [Related]
39. Dietary flaxseed enhances the inhibitory effect of tamoxifen on the growth of estrogen-dependent human breast cancer (mcf-7) in nude mice.
Chen J; Hui E; Ip T; Thompson LU
Clin Cancer Res; 2004 Nov; 10(22):7703-11. PubMed ID: 15570004
[TBL] [Abstract][Full Text] [Related]
40. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
Chu I; Blackwell K; Chen S; Slingerland J
Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]